Related Experiment Video
Updated: Jun 13, 2026

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
Published on: September 29, 2016
Signal transduction therapy of cancer
Alexander Levitzki1, Shoshana Klein
1Unit of Cellular Signaling, Department of Biological Chemistry, The Hebrew University of Jerusalem, Givat Ram, Jerusalem 91904, Israel. alex.levitzki@mail.huji.ac.il
Abstract:
Signal transduction therapy for cancer targets signaling elements with key roles in cancer cell survival and proliferation, but with more minor roles in the survival of healthy cells. Cancer cells have shrunken signaling networks, and therefore tend to be dependent on fewer signaling modules than non-cancerous cells. Thus, targeted therapy holds the promise of efficacy with minimal toxicity. Yet, with the notable exception of Gleevec for the treatment of early chronic myelogenous leukemia (CML), targeted therapies have so far had minimal success. Unlike early CML, which is dependent upon BCR-ABL, most cancers are not dependent on a single survival factor. Furthermore, tumors are constantly evolving entities, and are heterogeneous in their cellular makeup, compounding the challenge. "Smart cocktails", comprising rational combinations of therapies, need to be developed to meet this challenge. What are the best pathways to target, and why? What types of molecules can be developed into effective therapeutics? What combinations are likely to be successful? Here we present an overview of the principles that need to be considered in designing effective targeted therapy for cancer.
Insights
Targeted cancer therapies aim for efficacy with minimal toxicity by exploiting cancer cells' reliance on specific signaling pathways. Developing "smart cocktails" of therapies is crucial for overcoming tumor heterogeneity and evolving resistance.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Signal transduction therapy targets cancer-specific signaling pathways for improved efficacy and reduced toxicity.
- Cancer cells often exhibit 'shrunken' signaling networks, leading to dependencies on fewer modules compared to healthy cells.
- Despite promise, targeted therapies have seen limited success beyond specific cases like chronic myelogenous leukemia (CML).
Purpose of the Study:
- To explore the principles for designing effective targeted cancer therapies.
- To address challenges posed by tumor heterogeneity and evolving resistance.
- To investigate optimal pathways, therapeutic molecules, and combination strategies.
Main Methods:
- Review and synthesis of existing knowledge on cancer signaling pathways.
- Analysis of principles for developing targeted therapeutics.
- Consideration of rational combination strategies ('smart cocktails').
Main Results:
- Most cancers are not dependent on a single survival factor, unlike early CML.
- Tumor heterogeneity and evolution present significant challenges to targeted therapy.
- The development of 'smart cocktails' is proposed as a necessary approach.
Conclusions:
- Effective targeted cancer therapy requires a deep understanding of signaling networks and tumor biology.
- Rational combinations of therapies are essential to overcome resistance and heterogeneity.
- Further research is needed to identify optimal targets and combination strategies for broad clinical success.
More Related Videos
11:13Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
Published on: June 9, 2023
07:42Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
Published on: September 19, 2018
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Signal Transduction: Overview
Typically, signal transduction involves three...
Tumor Immunotherapy
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...